Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 10, 2013, Pages 2212-2219

  Vaquero, Javier ^a   Briz, Oscar ^a,c   Herraez, Elisa ^a   Muntané, Jordi ^b,c   Marin, Jose J G ^a,c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Bile acid; Cancer; Chemotherapy; Drug; Liver; Pharmacology

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ANTINEOPLASTIC AGENT; ARTESUNATE; BILE ACID; CISPLATIN; COLCHICINE; DICHROMATE POTASSIUM; DOXORUBICIN; FARNESOID X RECEPTOR; MITOMYCIN; PACLITAXEL; PARACETAMOL; SORAFENIB;

ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSFECTION; GENOTOXICITY; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; LIVER PROTECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION;

BILE ACID; CANCER; CHEMOTHERAPY; DRUG; FARNESOID X RECEPTOR; FXR; HCC; HEPATOCELLULAR CARCINOMA; LIVER; MECHANISMS OF CHEMORESISTANCE; MOC; PHARMACOLOGY; RETINOID X RECEPTOR; RXR; TAQMAN LOW DENSITY ARRAY; TLDA;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; ISOXAZOLES; LIVER NEOPLASMS; LUCIFERASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR MARKERS, BIOLOGICAL;

ARTESUNATE;

EID: 84879367153     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.05.006     Document Type: Article

References (39)

1. Marin J.J., Romero M.R., Briz O. Molecular bases of liver cancer refractoriness to pharmacological treatment. Curr. Med. Chem. 2010, 17:709-740.
2. Chong H.K., Infante A.M., Seo Y.K., Jeon T.I., Zhang Y., Edwards P.A., Xie X., Osborne T.F. Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1. Nucleic Acids Res. 2010, 38:6007-6017.
3. Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 2009, 89:147-191.
4. Kim I., Morimura K., Shah Y., Yang Q., Ward J.M., Gonzalez F.J. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007, 28:940-946.
5. Modica S., Murzilli S., Salvatore L., Schmidt D.R., Moschetta A. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res. 2008, 68:9589-9594.
6. Chen W.D., Wang Y.D., Zhang L., Shiah S., Wang M., Yang F., Yu D., Forman B.M., Huang W. Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription. Hepatology 2010, 51:953-962.
7. Inagaki T., Moschetta A., Lee Y.K., Peng L., Zhao G., Downes M., Yu R.T., Shelton J.M., Richardson J.A., Repa J.J., Mangelsdorf D.J., Kliewer S.A. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3920-3925.
8. Stedman C., Liddle C., Coulter S., Sonoda J., Alvarez J.G., Evans R.M., Downes M. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11323-11328.
9. Moschetta A., Bookout A.L., Mangelsdorf D.J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat. Med. 2004, 10:1352-1358.
10. Gnerre C., Blattler S., Kaufmann M.R., Looser R., Meyer U.A. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 2004, 14:635-645.
11. Barbier O., Torra I.P., Sirvent A., Claudel T., Blanquart C., Duran-Sandoval D., Kuipers F., Kosykh V., Fruchart J.C., Staels B. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 2003, 124:1926-1940.
12. Song C.S., Echchgadda I., Baek B.S., Ahn S.C., Oh T., Roy A.K., Chatterjee B. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J. Biol. Chem. 2001, 276:42549-42556.
13. Huang L., Zhao A., Lew J.L., Zhang T., Hrywna Y., Thompson J.R., de Pedro N., Royo I., Blevins R.A., Pelaez F., Wright S.D., Cui J. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J. Biol. Chem. 2003, 278:51085-51090.
14. Ananthanarayanan M., Balasubramanian N., Makishima M., Mangelsdorf D.J., Suchy F.J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 2001, 276:28857-28865.
15. Lee F.Y., de Aguiar Vallim T.Q., Chong H.K., Zhang Y., Liu Y., Jones S.A., Osborne T.F., Edwards P.A. Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity. Mol. Endocrinol. 2010, 24:1626-1636.
16. Herraez E., Gonzalez-Sanchez E., Vaquero J., Romero M.R., Serrano M.A., Marin J.J., Briz O. Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Mol. Pharm. 2012, 9:2565-2576.
17. Martinez-Becerra P., Vaquero J., Romero M.R., Lozano E., Anadon C., Macias R.I., Serrano M.A., Grane-Boladeras N., Munoz-Bellvis L., Alvarez L., Sangro B., Pastor-Anglada M., Marin J.J. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol. Pharm. 2012, 9:1693-1704.
18. Huber R.M., Murphy K., Miao B., Link J.R., Cunningham M.R., Rupar M.J., Gunyuzlu P.L., Haws T.F., Kassam A., Powell F., Hollis G.F., Young P.R., Mukherjee R., Burn T.C. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 2002, 290:35-43.
19. Gonzalez R., Cruz A., Ferrin G., Lopez-Cillero P., Fernandez-Rodriguez R., Briceno J., Gomez M.A., Rufian S., Mata Mde L., Martinez-Ruiz A., Marin J.J., Muntane J. Nitric oxide mimics transcriptional and post-translational regulation during alpha-tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes. J. Hepatol. 2011, 55:133-144.
20. Macias R.I., Hierro C., de Juan S.C., Jimenez F., Gonzalez-San Martin F., Marin J.J. Hepatic expression of sodium-dependent vitamin C transporters: ontogeny, subtissular distribution and effect of chronic liver diseases. Br. J. Nutr. 2011, 106:1814-1825.
21. Nytofte N.S., Serrano M.A., Monte M.J., Gonzalez-Sanchez E., Tumer Z., Ladefoged K., Briz O., Marin J.J. A homozygous nonsense mutation (c.214C->A) in the biliverdin reductase alpha gene (BLVRA) results in accumulation of biliverdin during episodes of cholestasis. J. Med. Genet. 2011, 48:219-225.
22. Frankenberg T., Miloh T., Chen F.Y., Ananthanarayanan M., Sun A.Q., Balasubramaniyan N., Arias I., Setchell K.D., Suchy F.J., Shneider B.L. The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology 2008, 48:1896-1905.
23. Gineste R., Sirvent A., Paumelle R., Helleboid S., Aquilina A., Darteil R., Hum D.W., Fruchart J.C., Staels B. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol. Endocrinol. 2008, 22:2433-2447.
24. Basu A., Tu H. Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cdelta. Biochem. Biophys. Res. Commun. 2005, 334:1068-1073.
25. Diaz Bessone M.I., Berardi D.E., Campodonico P.B., Todaro L.B., Lothstein L., Bal de Kier Joffe E.D., Urtreger A.J. Involvement of PKC delta (PKCdelta) in the resistance against different doxorubicin analogs. Breast Cancer Res. Treat. 2011, 126:577-587.
26. Jiang X.H., Tu S.P., Cui J.T., Lin M.C., Xia H.H., Wong W.M., Chan A.O., Yuen M.F., Jiang S.H., Lam S.K., Kung H.F., Soh J.W., Weinstein I.B., Wong B.C. Antisense targeting protein kinase C alpha and beta1 inhibits gastric carcinogenesis. Cancer Res. 2004, 64:5787-5794.
27. Kim D.H., Kim J., Lee J.W. Requirement for MLL3 in p53 regulation of hepatic expression of small heterodimer partner and bile acid homeostasis. Mol. Endocrinol. 2011, 25:2076-2083.
28. Trauner M., Boyer J.L. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 2003, 83:633-671.
29. Lecureur V., Sun D., Hargrove P., Schuetz E.G., Kim R.B., Lan L.B., Schuetz J.D. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol. Pharmacol. 2000, 57:24-35.
30. Ruetz S., Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 1994, 77:1071-1081.
31. Johnsson A., Vallon-Christensson J., Strand C., Litman T., Eriksen J. Gene expression profiling in chemoresistant variants of three cell lines of different origin. Anticancer. Res. 2005, 25:2661-2668.
32. Koike K., Kawabe T., Tanaka T., Toh S., Uchiumi T., Wada M., Akiyama S., Ono M., Kuwano M. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 1997, 57:5475-5479.
33. Cuesta E.P., Langhi C., Haro D., Marrero P.F., Rodriguez J.C. Transcription elongation factor TFIIS.1 gene is regulated by farnesoid X receptor. FEBS J. 2012, 279:276.
34. Tornaletti S., Patrick S.M., Turchi J.J., Hanawalt P.C. Behavior of T7 RNA polymerase and mammalian RNA polymerase II at site-specific cisplatin adducts in the template DNA. J. Biol. Chem. 2003, 278:35791-35797.
35. Patlolla A.K., Barnes C., Hackett D., Tchounwou P.B. Potassium dichromate induced cytotoxicity, genotoxicity and oxidative stress in human liver carcinoma (HepG2) cells. Int. J. Environ. Res. Public Health 2009, 6:643-653.
36. Liedtke C., Lambertz D., Schnepel N., Trautwein C. Molecular mechanism of Mitomycin C-dependent caspase-8 regulation: implications for apoptosis and synergism with interferon-alpha signalling. Apoptosis 2007, 12:2259-2270.
37. Lian F., Xing X., Yuan G., Schafer C., Rauser S., Walch A., Rocken C., Ebeling M., Wright M.B., Schmid R.M., Ebert M.P., Burgermeister E. Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage. Biochem. J. 2011, 438:315-323.
38. Efferth T., Sauerbrey A., Olbrich A., Gebhart E., Rauch P., Weber H.O., Hengstler J.G., Halatsch M.E., Volm M., Tew K.D., Ross D.D., Funk J.O. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 2003, 64:382-394.
39. Li Q., Shi L., Gui B., Yu W., Wang J., Zhang D., Han X., Yao Z., Shang Y. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res. 2011, 71:6899-6908.